

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re application of: **Rachel E. Meyers, et al.**

Application No.:

Group No.: **N/A**Filed: **Herewith**Examiner: **N/A**For: **21481, A NOVEL DEHYDROGENASE MOLECULE AND USES THEREFOR**

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (17 pages)
3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)**37 C.F.R. SECTION 1.10***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. 1L992152684US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: September 17, 2003

Sean Hunziker
(type or print name of person certifying)

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No. 09/838,561, filed on April 18, 2001.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

September 17, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By


Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone - (617) 551-3676
Facsimile - (617) 551-8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

64

1

1

Complete if Known

Application Number	Herewith
Filing Date	Rachel E. Meyers, et al.
First Named Inventor	
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	MP100-079P1RCP2CN1M

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Code ⁵ Office ³	Number ⁴ (if known)			
B1	WO	98/39448			9/98	
B2	WO	99/14328			3/99	
B3	WO	99/33982			7/99	
B4	WO	99/38972			8/99	
B5	WO	00/00621			01/00	
B6	WO	00/15796			04/00	
B7	WO	00/17222			03/00	
B8	WO	00/18916			04/00	
B9	WO	00/20604			04/00	
B10	WO	00/53757			09/00	
B11	WO	00/55174			10/00	
B12	WO	00/58496			10/00	
B13	WO	00/77023			12/00	
B14	WO	01/02568			01/01	
B15	EP	1033401			09/00	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached *Kinds of U.S. Patent Documents*. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

SONG: SEND THIS ON DOWN THE LINE

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

		Complete if Known	
Sheet	1	of	1
			Attorney Docket Number

Application Number	
Filing Date	Herewith
First Named Inventor	Rachel E. Meyers, et al.
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	MP100-079P1RCP2CN1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Akbar S. K., et al., <i>Int. J. Exp. Pathol.</i> 79(3):279-291 (1998)	
	C2	Akbar, S. M. F., et al., <i>Eur. J. Clin. Invest.</i> 29(9):786-792 (1999)	
	C3	Almond, N. et al., <i>Immunol. Lett.</i> 66(1-3):167-170 (1999)	
	C4	Andersson, B. et al., <i>Anal. Biochem.</i> 236(1):107-113 (1996)	
	C5	Babinet, C. et al., <i>Science</i> 230(4730):1160-1163 (1985)	
	C6	Blasco, R. et al., <i>J. Virol.</i> 65(9):4598-4608 (1991)	
	C7	Bocher, W. O. et al., <i>Hepatology</i> 31(2):480-487 (2000)	
	C8	Brown, J. J., et al., <i>Hepatology</i> 31(1):173-181 (2000)	
	C9	Butel, J. S., <i>Carcinogenesis</i> 21(3):405-426 (2000)	
	C10	Cavanaugh, V. J., et al., <i>J. Virol.</i> 72(4):2630-2637 (1998)	
	C11	Cavanaugh, V. J., et al., <i>J. Virol.</i> 71(4):3236-3243 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Compl te if Known

Sheet	2	of	16	Attorney Docket Number	«FileRefNo»
-------	---	----	----	------------------------	-------------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C12	Chou, C. K., et al., <i>Hepatology</i> 16(1):13-18 (1992)	
	C13	Cote, P. et al., <i>Hepatology</i> 31(1):190-200 (2000)	
	C14	Das, A. K., et al., <i>J. Biol. Chem.</i> 275(32):24333-24340 (2000)	
	C15	Douglas, N. J., et al., <i>J. Gen. Virol.</i> 77(pt. 12):3113-3120 (1996)	
	C16	Farza, H. et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84(5):1187-1191 (1987)	
	C17	Fenner, F., <i>FEMS Microbiol. Rev.</i> 24(2):123-133 (2000)	
	C18	Gripion, P. et al., <i>J. Med. Virol.</i> 28(3):193-199 (1989)	
	C19	LeGuerhier, F. et al., <i>Antimicrob. Agents Chemother.</i> 44(1):111-122 (2000)	
	C20	Guidotti, L. G., et al., <i>J. Virol.</i> 69(10):6158-6169 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

Sheet

3 of 16

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	Hayashi, Y. et al., <i>Biochim. Biophys. Acta.</i> 1352(2):145-150 (1997)	
	C22	Hayashi, K. et al., <i>Pathol. Int.</i> 50(2):85-97 (2000)	
	C23	Heise, T. et al., <i>J. Virol.</i> 73(1):474-481 (1999)	
	C24	Hsu, L. et al., <i>Gene</i> 174(2):319-322 (1996)	
	C25	Ilan, E. et al., <i>Hepatology</i> 29(2): 553-562 (1999)	
	C26	Kisseljov, F. L., <i>Biochemistry</i> 65(1):68-77 (2000)	
	C27	Korba, B. E. et al., <i>Hepatology</i> 31(5):1165-1175 (2000)	
	C28	Koziel, M. J., <i>Antivir. Ther.</i> 3(Suppl 3):13-24 (1998)	
	C29	Lai, C. H., et al., <i>Genome Res.</i> 10(5):703-713 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and

Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4 of 16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C30	Larkin, J. et al., <i>Nat. Med.</i> 5(8):907-912 (1999)	
	C31	Madden, C. R., et al., <i>J. Virol.</i> 74(11):5266-5272 (2000)	
	C32	Niewiesk, S., <i>Immunol. Lett.</i> 65(1-2):47-50 (1999)	
	C33	Ohashi, K. et al., <i>Nat. Med.</i> 6(3):327-331 (2000)	
	C34	Pasquinelli, C. et al., <i>Hepatology</i> 25(3):719-727 (1997)	
	C35	Renard, C. A., et al. <i>Res. Virol.</i> 149(3):133-143 (1998)	
	C36	Sakai, N. et al., <i>FEBS Lett.</i> 350(2-3):309-313 (1994)	
	C37	Schat, K. A., et al., <i>Dev. Comp. Immunol.</i> 24(2-3):201-221 (2000)	
	C38	Schwarz, M. et al., <i>J. Clin. Invest.</i> 106(9):1175-1184 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5 of 16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C39	Seeger, C. et al., <i>Microbiol. Mol. Biol. Rev.</i> 64(1):51-68 (2000)	
	C40	Senkevich, T. G. et al., <i>Science</i> 273(5276):813-816 (1996)	
	C41	Shimoda, N. et al., <i>Genomics</i> 58(3):219-232 (1999)	
	C42	Torresi, J. et al., <i>Gastroenterology</i> 118(2 Suppl 1):S83-103 (2000)	
	C43	Tur-Kaspa, R. et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> 83(6):1627-1631 (1986)	
	C44	Vickery, K. et al., <i>J. Med. Virol.</i> 58(1):19-25 (1999)	
	C45	Virgin, H. W. et al., <i>Curr. Opin. Immunol.</i> 11(4):371-379 (1999)	
	C46	Wieland, S. F. et al., <i>J. Virol.</i> 74(9):4165-4173 (2000)	
	C47	Wiemann, S. et al., <i>Genome Res.</i> 11(3):422-435 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C48	Zhang, J. et al., <i>Biochim. Biophys. Acta.</i> 1435(1-2):184-190 (1999)	
	C49	Zhao, H. F. et al., <i>FEBS Lett.</i> 259(1):153-157 (1989)	
	C50	Results of BLASTN search of nucleic acid patent database using DHDR-4 nucleotide sequence	
	C51	Results of BLASTN search of nucleic acid patent database using DHDR-1 nucleotide sequence	
	C52	Results of BLASTN search of GenBank database (dbEST) using DHDR-2 nucleotide sequence	
	C53	Results of BLASTN search of nucleic acid patent database (FastAlert_N) using DHDR-2 nucleotide sequence	
	C54	Results of BLASTN search of GenBank database (nucleic acid) using DHDR-2 nucleotide sequence	
	C55	Results of BLASTN search of nucleic acid patent database (PatentDbPreviewNuc) using DHDR-2 nucleotide sequence	
	C56	Results of BLASTN search of GenBank database (dbEST) using DHDR-4 nucleotide sequence	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

16

Compliant if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C57	Results of BLASTN search of GenBank database (nucleic acid) using DHDR-4 nucleotide sequence	
	C58	Results of BLASTX search of GenBank database (protein) using DHDR-4 predicted polypeptide sequence	
	C59	Results of BLASTN search of nucleic acid patent database (PatentDbPreviewNuc) using DHDR-4 nucleotide sequence	
	C60	Results of BLASTN search of GenBank database (dbEST) using DHDR-3 nucleotide sequence	
	C61	Results of BLASTN search of nucleic acid patent database (FastAlert_N) using DHDR-3 nucleotide sequence	
	C62	Results of BLASTX search of protein patent database (FastAlert_P) using DHDR-3 predicted polypeptide sequence	
	C63	Results of BLASTN search of GenBank database (nucleic acid) using DHDR-3 nucleotide sequence	
	C64	Results of BLASTN search of nucleic acid patent database (PatentDbPreviewNuc) using DHDR-3 nucleotide sequence	
	C65	Results of BLASTX search of protein patent database using DHDR-3 predicted polypeptide sequence	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C66	Results of BLASTN search of GenBank database (dbEST) using DHDR-1 nucleotide sequence	
	C67	Results of BLASTN search of nucleic acid patent database (FastAlert_N) using DHDR-1 nucleotide sequence	
	C68	Results of BLASTN search of GenBank database (nucleic acid) using DHDR-1 nucleotide sequence	
	C69	GenSeq Accession No. C09039 for Human secreted protein 5' EST, SEQ ID NO. 13114	
	C70	GenSeq Accession No. X98422 for Human cancer cell derived cDNA #148	
	C71	GenSeq Accession No. X99042 for Human validated cancer cell derived cDNA #364	
	C72	GenBank Accession No. AI091419 for ow62e03.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1651420 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.3 MER22 repetitive element; mRNA sequence	
	C73	GenBank Accession No. AI741629 for wg28f07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:2366437 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.3 MER22 repetitive element; mRNA sequence	
	C74	GenBank Accession No. AI741640 for wg28g07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:2366460 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.3 MER22 repetitive element; mRNA sequence	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	9	of	16	Attorney Docket Number	«FileRefNo»
-------	---	----	----	------------------------	-------------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C75	GenBank Accession No. AI458236 for tq53e07.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:2145252 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C76	GenBank Accession No. AI222126 for qh02g04.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1845452 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C77	GenBank Accession No. AA953672 for oo02e08.s1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1565030 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C78	GenBank Accession No. AI376903 for tc27f05.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:2065857 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C79	GenBank Accession No. AI141463 for qa67d12.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1691831 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C80	GenBank Accession No. AI022337 for ow95a11.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1654556 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C81	GenBank Accession No. AI168267 for oo10c10.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo Sapiens cDNA clone IMAGE:1565778 3' similar to WP: T25G12.7 CE07544 DEHYDROGENASE; contains TAR1.I3 MER22 repetitive element; mRNA sequence	
	C82	GenBank Accession No. AF151851 for Homo sapiens CG1-93 protein mRNA, complete cds.	
	C83	GenBank Accession No. AL117567 for Homo sapiens mRNA; cDNA DKFZp566O084 (from clone DKFZp566o084); complete cds.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10 of 16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Name of Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C84	GenBank Accession No. G41333 for Z1176 Zebrafish AB Danio rerio STS genomic, sequence tagged site	
	C85	GenBank Accession No. AV652436 for AV652436 GLC Homo sapiens cDNA clone GLCDAD01 3'. mRNA sequence	
	C86	GenBank Accession No. AI765848 for wi85c03.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone IMAGE:2400100 3' similar to TR: Q42232 Q42232 TROPINONE REDUCTASE HOMOLOGUE; mRNA sequence	
	C87	GenBank Accession No. BE220231 for hv69f02.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:3178683 3' similar to TR: Q9ZW14 Q9ZW14 PUTATIVE TROPINONE REDUCTASE; mRNA sequence	
	C88	GenBank Accession No. BF108369 for 7n6f05.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:3569408 3' similar to TR: Q9WVK3 Q9WVK3 PUTATIVE SHORT-CHAIN DEHYDROGENASE/REDUCTASE mRNA, COMPLETE CDS.	
	C89	GenBank Accession No. BE550902 for 7b65g01.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:3233136 3' similar to SW: YKUF_BACSU O34717 HYPOTHETICAL OXIDOREDUCTASE IN CHEV-MOBA INTERGENIC REGION	
	C90	GenBank Accession No. AI435448 for th94e11.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone IMAGE:2126348 3' similar to SW: FABG_MYCTU Q48930 3-OXOACYL-[ACYL-CARRIER PROTEIN] REDUCTASE	
	C91	GenBank Accession No. BE300277 for 600944051T1 NIH_MGC_17 Homo sapiens cDNA clone IMAGE:2960244 3', mRNA sequence	
	C92	GenBank Accession No. BE280956 for 601155875F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:3139219 5', mRNA sequence	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

11

of

16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C93	GenBank Accession No. BE382385 for 601815316F2 NIH_MGC_17 Homo sapiens cDNA clone IMAGE:40494995, mRNA sequence	
	C94	GenBank Accession No. BF726019 for bx23a05.y1 Human Iris cDNA (Un-normalized, unamplified); BX Homo sapiens cDNA clone bx23a05 5', mRNA sequence	
	C95	GenBank Accession No. AF232009 for Homo sapiens peroxisomal trans 2-enoyl CoA reductase mRNA, complete cds.	
	C96	GenBank Accession No. AJ250303 for Homo sapiens mRNA for putative short chain alcohol dehydrogenase	
	C97	GenBank Accession No. AF119841 for Homo sapiens PRO 1004 mRNA, complete cds.	
	C98	GenBank Accession No. AF232010 for Cavia sp. peroxisomal trans 2-enoyl CoA reductase mRNA, complete cds.	
	C99	GenBank Accession No. AF099742 for Rattus norvegicus putative short-chain dehydrogenase/reductase mRNA, complete cds.	
	C100	GenBank Accession No. AF021854 for Rattus norvegicus peroxisomal trans 2-enoyl CoA reductase px-2, 4-DCR#1 mRNA, complete cds.	
	C101	GenBank Accession No. AF232011 for Mus musculus peroxisomal trans 2-enoyl CoA reductase mRNA, complete cds.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

12

of

16

Complaint if Known

Application Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C102	GenBank Accession No. AR007559 for Sequence 2 from Patent US 5750873	
	C103	GenBank Accession No. BF569876 for 602185823F1 NIH_MGC_45 Homo sapiens cDNA clone IMAGE:4310212 5', mRNA sequence	
	C104	GenBank Accession No. BF569788 for 602185723F1 NIH_MGC_45 Homo sapiens cDNA clone IMAGE:4310213 5', mRNA sequence	
	C105	GenBank Accession No. BF337229 for 602035036F1 NIH_CGAP_Bm64 Homo sapiens cDNA clone IMAGE:4182969 5', mRNA sequence	
	C106	GenBank Accession No. BE389320 for 601286201F1 NIH_MGC_44 Homo sapiens cDNA clone IMAGE:3612936 5', mRNA sequence	
	C107	GenBank Accession No. BE393409 for 601308354F1 NIH_MGC_44 Homo sapiens cDNA clone IMAGE:3626629 5', mRNA sequence	
	C108	GenBank Accession No. BF533271 for 602073726F1 NIH_CGAP_Li9 Mus musculus cDNA clone IMAGE:4210518 5', mRNA sequence	
	C109	GenBank Accession No. BF535721 for 602051225F1 NIH_CGAP_SG2 Mus musculus cDNA clone IMAGE:4190478 5', mRNA sequence	
	C110	GenBank Accession No. BF532852 for 602074958F1 NIH_CGAP_Li9 Mus musculus cDNA clone IMAGE:4211726 5', mRNA sequence	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

13

of

16

C *mpl te if Known*

Applicant Number	«AppNumber»
Filing Date	«Filing_Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C110	GenBank Accession No. BF236705 for 602028695F1 NIH_CGAP_Li9 Mus musculus cDNA clone IMAGE:4163927 5', mRNA sequence	
	C111	GenBank Accession No. BE808024 for 213133 MARC 2BOV Bos Taurus cDNA 5', mRNA sequence	
	C112	GenBank Accession No. AF277719 for Homo sapiens 3 beta-hydroxy-delta 5-C27-steroid oxidoreductase mRNA, complete cds.	
	C113	GenBank Accession No. AF277718 for Mus musculus sapiens 3 beta-hydroxy-delta 5-C27-steroid oxidoreductase mRNA, complete cds.	
	C114	GenBank Accession No. AB000199 for Rattus norvegicus cca2 mRNA, complete cds.	
	C115	GenBank Accession No. S72665 for Ig V-D-J region (RM) – human (fragment)	
	C116	GenBank Accession No. AF232699 for Sus scrofa 3 beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase (3b-HSD) mRNA, 3b-HSD-1 allele, complete cds.	
	C117	GenBank Accession No. X17614 for Bovine mRNA for 3 beta hydroxy-5-ene steroid dehydrogenase/delta-5-delta-4 isomerase (EC 1.1.1.145, EC 5.3.3.1)	
	C118	GenBank Accession No. U32426 for Molluscum contagiosum virus 3-beta hydroxy-5-ene steroid dehydrogenase (CX11) gene, complete cds.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				
Sheet	14	of	16	Attorney Docket Number
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C119	GenBank Accession No. U86945 for <i>Molluscum contagiosum</i> virus subtype 1 clone H-M ; H-N homolog of vaccinia A36R (H-M-N-1), hypothetical protein (H-M-N-2), putative CC chemokine (H-M-N-3), homolog of vaccinia A37R (H-M-N-4), hypothetical protein (H-M-N-5), hypothetical protein (H-M-N-6) and homolog of vaccinia A44L (H-M-N-7) genes, complete cds, and hypothetical protein (H-M-N-8 gene, partial cds.			
	C120	GenBank Accession No. U60315 for <i>Molluscum contagiosum</i> virus subtype 1, complete genome			
	C121	GenBank Accession No. M72474 for Vaccinia virus gene ORF2, ORF3, ORF4, ORF5, ORF6, and ORF7 complete cds ; ORF1, 5' end ; ORF8, 3' end			
	C122	GenBank Accession No. AI863355 for tz47c11.x1 NCI_CGAP_Bm52 Homo sapiens cDNA clone IMAGE:2291732 3' similar to TR:O50217 O50217 PHENYLACE-TALDEHYDE DEHYDROGENASE ; mRNA sequence			
	C123	GenBank Accession No. AI863364 for tz47d11.x1 NCI_CGAP_Bm52 Homo sapiens cDNA clone IMAGE:2291733 3' similar to SW:YDCW_ECOLI P77674 PUTATIVE BETAINE ALDEHYDE DEHYDROGENASE; mRNA sequence			
	C124	GenBank Accession No. BE048206 for tz47c11.y1 NCI_CGAP_Brn52 Homo sapiens cDNA clone IMAGE:2291732 5' similar to SW:FEAB_ECOLI P80668 PHENYLACETALDEHYDE DEHYDROGENASE; mRNA sequence			
	C125	GenBank Accession No. AI674922 for wc73g08.x1 NCI_CGAP_Pan1 Homo sapiens cDNA clone IMAGE:2324318 3' similar to TR:O50217 O50217 PHENYLACE-TALDEHYDE DEHYDROGENASE; mRNA sequence			
	C126	GenBank Accession No. BE048060 for tz47d11.y1 NCI_CGAP_Brn52 Homo sapiens cDNA clone IMAGE:2291733 5' similar to SW:FEAB_ECOLI P80668 PHENYLACETALDEHYDE DEHYDROGENASE; mRNA sequence			
	C127	GenBank Accession No. BE734592 for 601569937F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:3844689 5', mRNA sequence			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

15

of

16

Complete if Known

Application Number	«AppNumber»
Filing Date	«Filing Date»
First Named Inventor	«Inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C128	GenBank Accession No. BE902065 for 601674824F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:3957749 5', mRNA sequence	
	C129	GenBank Accession No. BF189846 for 235590 MARC 2PIG Sus scrofa cDNA 5', mRNA sequence	
	C130	GenBank Accession No. AI754389 for cr24e02.x1 Jia bone marrow stroma Homo sapiens cDNA clone HBMSC_cr24e02 3', mRNA sequence	
	C131	GenBank Accession No. BE235576 for 143113 MARC 1PIG Sus scrofa cDNA 5', mRNA sequence	
	C132	GenBank Accession No. AY00796 for Homo sapiens clone TCCCIA00164 mRNA sequence	
	C133	GenBank Accession No. AX070214 for Sequence 686 from Patent WO0102568	
	C134	GenBank Accession No. AX072164 for Sequence 2636 from Patent WO0102568	
	C135	GenBank Accession No. AX070075 for Sequence 547 from Patent WO0102568	
	C136	GenBank Accession No. AK024182 for Homo sapiens cDNA FLJ14120 f1s, clone MAMMA 1001956	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

She

6

16

<i>Completer if Known</i>	
Application Number	«AppNumber»
Filing Date	«Filing Date»
First Named Inventor	«inventor1»
Group Art Unit	
Examiner Name	
Attorney Docket Number	«FileRefNo»

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation design number. **Applicant is to place a check mark here if English language translation is desired.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20591.